Advertisement

Thrombolytic Therapy in Acute Ischemic Stroke: Combination Therapy with Antiplatelet and Anticoagulant Agents

  • N. G. Wahlgren
Conference paper

Abstract

No randomized clinical trials have been performed to evaluate the effect of thrombolytic therapy combined with anticoagulant or antiplatelet agents in acute ischemic stroke. Data on the effect on acute stroke and the risk for cerebral hemorrhage of combined thrombolytic and antiplatelet therapy [1] and thrombolytic and anticoagulant treatment along with antiplatelets, however, can be derived from randomized clinical trials of more than 100000 patients with evolving myocardial infarction, a condition associated with acute stroke in about 1% of the cases [2–4].

Keywords

Acute Stroke Acute Ischemic Stroke Thrombolytic Therapy Hemorrhagic Stroke Intravenous Heparin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomized clinical trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349–360Google Scholar
  2. 2.
    Gruppo Italiano per la Studio della Sopravvivivenza nell’ Infarto Miocardico (1990) GISSI2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 336: 65–71Google Scholar
  3. 3.
    The GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673–682CrossRefGoogle Scholar
  4. 4.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group (1992) ISIS-3: a randomized comparison of streptokinase, versus tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction: ISIS-2. Lancet 339: 753–770CrossRefGoogle Scholar
  5. 5.
    Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G, the Gruppo Italiano per lo Studio della Sopravvivivenza nell’ Infarto Miocardico II (GISSI-2) and International Study Group (1991) The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 327: 1–6CrossRefGoogle Scholar
  6. 6.
    Fitzgerald DJ, Catalla F, Roy L, Fitzgerald GA (1988) Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77: 142–150PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • N. G. Wahlgren
    • 1
  1. 1.Department of NeurologyKarolinska sjukhusetStockholmSweden

Personalised recommendations